Clinical Trial Update: Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts [Phase 3]

View source ↗

Summary

A Phase 3 multicenter trial in myelodysplastic syndromes without excess blasts comparing erythropoietin alone to erythropoietin with differentiating therapy usi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• 13-cis-retinoic acid (13-cis-retinoic acid)
• Dihydroxyvitamin D3 (1,25-dihydroxyvitamin D3)
• Erythropoietin (erythropoietin)

Snippet

Sponsor: Fondazione Italiana Sindromi Mielodisplastiche-ETS | Conditions: Myelodysplastic Syndromes | Phase 3 | Status: TERMINATED